News Releases

25 Aug '21
Cortexyme Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimer’s Disease at Annual Biomarkers for Alzheimer’s Disease Summit
GAIN Trial analysis of anti-P. gingivalis antibodies in cerebrospinal fluid supports upstream role of pathogenic bacterium in key Alzheimer’s pathologies SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 25, 2021-- Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s
PDF Version
26 Jul '21
Cortexyme Presents Data Linking P. Gingivalis to Elevated Levels of Phospho-tau217 Reinforcing Evidence of Pathogen as Causative Agent of Alzheimer’s Disease at AAIC 2021
New GAIN Trial baseline data demonstrates majority of patients have elevated   Von Willebrand factor and alpha-2-macroglobulin Cortexyme to host AAIC symposium titled “Getting to the Root Cause of Alzheimer’s Disease: An Innovative, Upstream Approach for Disease Modification” on Tuesday, July 27
PDF Version
22 Jul '21
Cortexyme to Present New Data at AAIC 2021
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 22, 2021-- Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases , announced that it
PDF Version
Displaying 1 - 10 of 22